 |
|
Biomarkers of Alzheimer Disease
John H. Growdon, MD
Arch Neurol. 1999;56:281-283.
A definitive diagnosis of Alzheimer disease (AD) depends on finding widespread neurofibrillary tangles and plentiful neuritic plaques in the brain of an individual with a clinical diagnosis of progressive dementia.1 Using contemporary diagnostic criteria, the antemortem diagnosis of probable AD in centers specialized for AD is confirmed 80% to 90% of the time. There is the suspicion, but no firm data, that diagnostic accuracy is much lower outside of practices dedicated to patients with dementia. Furthermore, the diagnostic workup is expensive. In most settings, the evaluation generally includes a careful medical history and physical examination; neurologic examination (and psychiatric consultation as indicated); laboratory blood studies to exclude underlying metabolic and medical illnesses that masquerade as AD; a mental status assessment and formal cognitive tests; and a computed tomographic scan or magnetic resonance imaging of the brain.2 Because these procedures are time-consuming and costly, there is a need to identify biological tests that can circumvent aspects of this workup and point the physician to the correct diagnosis. It would be highly desirable to measure a subtance or substances in blood or urine samples or cerebrospinal fluid (CSF) that would lead to a positive diagnosis of AD without the need for specialized dementia clinics and the expense and time of standard diagnostic evaluations. In response to this need, the Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging convened a working group in 1997 to examine the status of various antemortem markers for AD. The consensus statement of this group, entitled "Molecular and Biochemical Markers of AD," was published in 1998.3 The consensus statement first defined the characteristics of an ideal biomarker, and then outlined the steps required for a proposed biomarker to achieve acceptance by the medical community. Finally, the statement reviewed the current state of all proposed biological markers. The workshop participants observed that none of the current biomarkers had yet achieved universal acceptance and concluded none fully met the consensus criteria for an ideal marker. Nonetheless, several tests were identified as good markers for familial AD, and several other tests showed promise as a diagnostic aid for sporadic AD. The purpose of this review is to put these recommendations into a practical context. What does the consensus statement tell the practicing clinician? How do the opinions in the consensus statement affect clinical practice in diagnosing and treating patients with dementia?
|
From the Department of Neurology, Massachusetts General Hospital, Boston, Mass.
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(3):370-371.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem 1H MR Spectroscopy Metabolite Measurements
Kantarci et al.
Radiology 2008;248:210-220.
ABSTRACT
| FULL TEXT
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic et al.
Brain 2008;131:1630-1645.
ABSTRACT
| FULL TEXT
Cerebrospinal Fluid Tau and {beta}-Amyloid: How Well Do These Biomarkers Reflect Autopsy-Confirmed Dementia Diagnoses?
Clark et al.
Arch Neurol 2003;60:1696-1702.
ABSTRACT
| FULL TEXT
Biochemical Diagnosis of Alzheimer Disease by Measuring the Cerebrospinal Fluid Ratio of Phosphorylated tau Protein to {beta}-Amyloid Peptide42
Maddalena et al.
Arch Neurol 2003;60:1202-1206.
ABSTRACT
| FULL TEXT
Anesthesia, the aging brain, and the surgical patient
Crosby and Culley
Canadian J. Anesthesia 2003;50:R12-12.
FULL TEXT
Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies
Clark and Karlawish
ANN INTERN MED 2003;138:400-410.
ABSTRACT
| FULL TEXT
Levels of Nonphosphorylated and Phosphorylated Tau in Cerebrospinal Fluid of Alzheimer's Disease Patients : An Ultrasensitive Bienzyme-Substrate-Recycle Enzyme-Linked Immunosorbent Assay
Hu et al.
Am. J. Pathol. 2002;160:1269-1278.
ABSTRACT
| FULL TEXT
Amyloid precursor protein in platelets: A peripheral marker for the diagnosis of sporadic AD
Padovani et al.
Neurology 2001;57:2243-2248.
ABSTRACT
| FULL TEXT
Biomarker Identification by Feature Wrappers
Xiong et al.
Genome Res 2001;11:1878-1887.
ABSTRACT
| FULL TEXT
Altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with Alzheimer's disease
Saez-Valero et al.
J. Neurol. Neurosurg. Psychiatry 2000;69:664-667.
ABSTRACT
| FULL TEXT
Neurology and psychiatry: Closing the great divide
Price et al.
Neurology 2000;54:8-8.
FULL TEXT
|
